Kiniksa preps BLA as Regeneron drug cruises to a PhIII win — shares soar
Kiniksa made a modest $5 million cash bet on Regeneron’s Arcalyst (rilonacept) back in 2017. The startup forged a pact to use the drug, which targets IL-1α and IL-1β, and see how it works against recurrent pericarditis, agreeing to split any profits to come while putting another $27 million in milestones up for grabs.
And the wager paid off handsomely today, as the biotech’s stock surged on their report of a Phase III success that sets up a near-term FDA application. The drug has already won the FDA’s breakthrough drug designation here, heightening expectations of a regulatory success.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
